Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. AMENDMENT NO. 1 TO COLLABORATION AND...Collaboration and License Agreement • August 13th, 2024 • Kezar Life Sciences, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of July 2, 2024 (the “First Amendment Effective Date”), by and between KEZAR LIFE SCIENCES, INC., a Delaware corporation having an address at 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080 (“Kezar”), EVEREST MEDICINES II (HK) LIMITED, a Hong Kong company with limited liability having an address at Unit 417 4/F, Lippo Centre Tower Two, No.89 Queensway Admiralty, HK (“Everest”), and solely for purposes of Section 4 (Acknowledgement of Guarantee) of this Amendment, EVEREST MEDICINES LIMITED, a Cayman Islands company with limited liability having an address at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“Guarantor”). Kezar, Everest and Guarantor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
